Welcome to the eilslabs

The eilslabs form a joint research group between the division "Theoretical Bioinformatics" at the German Cancer Research Center (dkfz) and the department Bioinformatics and Functional Genomics at the Institute of Pharmacy and Molecular Biotechnology (IPMB) at Heidelberg University. The group is headed by Prof. Roland Eils.


In a recent interview in the Frankfurter Allgemeine Sonntagszeitung, Roland Eils and Christof von Kalle (NCT) stress the importance of genome sequencing approaches for cancer diagnosis and targeted therapy. Von Kalle sees a “fascinating potential to access all available information on the disease of our cancer patients to help making more intelligent decisions at the bedside”. A prominent example of how the analysis of cancer genomes will influence cancer therapy is the discovery that pilocytic astrocytoma is a single pathway disease, recently published by the Lichter and Eils group at DKFZ (see below and Jones, Hutter, Jäger et al., Nature Genetics 2013). Moreover, “since three years, many lung cancer patients are stratified according to a genetic diagnosis, which identifies cancer subtypes and determines their therapy” says von Kalle. During the interview, Roland Eils emphasizes the constant need of new investments in IT infrastructure and personnel for handling and analysis of large amounts of data: “companies like Twitter have a hundred times more personnel to handle their data flow, though data volumes are comparable”. The interview is available online (in German only).


Pilocytic Astrocytoma - identified as a single pathway disease through whole genome sequencing


For further information please see the news feature: Pilocytic astrocytoma is predominantly a single-pathway disease

Source: Reprinted by permission from Macmillan Publishers Ltd: Jones, D. T. W., Hutter, B., Jager, N., et al. (2013). Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nature Genetics, doi: 10.1038/ng.2682